Agrochemicals company Astec Lifesciences Announced Q1FY23 Result : Q1FY23 consolidated total income increased by 44.4% YoY Q1FY23 consolidated EBITDA grew by 10.6% YoY, EBITDA margin stood at 15.3% Q1FY23 Profit after tax declined by 12.2% YoY Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said: Astec delivered 44.4% growth in total income in Q1FY23 driven by robust realisations in export markets. However, our strong topline performance was impacted by deferment of sales to the next quarter, to the tune of ~20% of Q1 revenues. Consequently, Profit after tax (PAT) declined by 12.2% to Rs. 11.4 Crore in Q1FY23. It should be noted that these sales deferrals are temporary and will be accounted for in the second quarter. Result PDF
Agrochemicals company Astec Lifesciences announced Q4FY22 results: Q4 FY22: Q4 FY22 consolidated total income increased by 60.7% YoY Q4 FY22 consolidated EBITDA grew by 81.8% YoY, EBITDA margin improved by 345bps Q4 FY22 Profit after tax grew by 79.7% YoY FY22: FY22 consolidated total income increased by 22.1% YoY FY22 consolidated EBITDA grew by 37.7% YoY, EBITDA margin improved by 279bps FY22 Profit after tax grew by 38.1% YoY Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said: "We delivered our best quarterly performance till date with highest ever total income of Rs. 278.8 Crore and Profit after tax (PAT) of Rs. 43.0 Crore in Q4 FY22. Total income grew by 60.7% year-onyear while PAT grew by 79.7% year-on-year. The remarkable growth was supported by strong realizations in export markets and healthy volume growth in contract manufacturing (CMO). In terms of full year results, it was another year of stellar performance, with growth of 22.1% in total income and 38.1% in profit after tax, year-on-year, respectively. Robust topline performance accompanied by improvement in profitability was driven by higher realizations in exports, favorable product mix, and operational efficiencies." Result PDF
Agrochemicals company Astec Lifesciences declares Q3FY22 result: For the third quarter ended December 31, 2021, company reported consolidated total income of Rs.175.3 crore, an increase of 47.0% year-on-year. Consolidated EBITDA and Profit before tax increased to Rs. 44.8 Crore and Rs. 33.2 Crore respectively, as compared to Rs.18.9 Crore and Rs.11.3 Crore during same quarter last year. For the first nine months ended December 31, 2021, company reported consolidated total income of Rs.408.2 crore, an increase of 4.9% year-on-year. Consolidated EBITDA and profit before tax also increased to 92.3 crore and Rs.62.8 crore respectively, a year-over-year increase of 15.7% and 10.4%. Commenting on the performance of the Q3FY22, Mr. Ashok Hiremath, Managing Director, Astec LifeSciences Limited, said: I am pleased to share with you the financials of Astec LifeSciences Limited for the quarter ended December 31st, 2021. Consolidated total income was Rs.175.3 crore, registering a growth of 47.0% year-on-year. Consolidated profit before tax was Rs.33.2 crore, registering a growth of 194.5% year-on-year. It was one of our best quarterly performances, supported by favorable product mix, strategic sourcing and good price realizations in both exports as well as domestic markets. Margins improved on the back of improved efficiencies and the reasons stated above. Result PDF